SavedAdd your journal

Journals / The European Research Journal / 2019 / Cilt: 5 - Sayı: 3

Evaluation of plasma catestatin levels in patient with coronary slow flow

Dursun TOPAL
Bedrettin BOYRAZ
Alkame AKGÜMÜŞ
Tezcan PEKER
Mustafa YILMAZ
Fahriye VATANSEVER
Selçuk KANAT
Ömür AYDIN
Burhan ARSLAN
Pages
522–528
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Coronary slow flow that increased catecholaminergic sympathetic system activities seem to be among the reasons of endothelial dysfunction.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Coronary slow flow (CSF) is characterized by delayed opasification of the coronary arteries in the absence of obstructive coronary disease.
📊
Key Findings & Data:This study included 45 CSF patients (37 male, mean age 48 ± 9.5 years) and 30 control individuals (24 male, mean age 48.4 ± 9 years).
💡
Conclusion & Impact:Coronary slow flow that increased catecholaminergic sympathetic system activities seem to be among the reasons of endothelial dysfunction.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:catestatin · coronary slow flow · coronary artery disease

Abstract

Objectives: Coronary slow flow (CSF) is characterized by delayed opasification of the coronary arteries in the absence of obstructive coronary disease. Catestatin has several cardiovasculer actions, in addition to diminihed sympato-adrenal flow. The study was to investigated associations between CSF and plasma catestatin levels. Method:. This study included 45 CSF patients (37 male, mean age 48 ± 9.5 years) and 30 control individuals (24 male, mean age 48.4 ± 9 years). Coronary flow was quantified according to the TIMI (Thrombolysis in Myocardial Infarction) frame count method for coronary arteries. Serum catestatin levels taken from blood samples were measured by ELISA method. These parameters were compared between the groups. Results: When compared with to the control group the serum catestatin levels was found higher in the CSF group. In addition to this, mean platelet volume was also significantly higher in patients with coronary slow flow. Conclusions: Our study revealed that catestatin levels are increased in patients with CSF. Coronary slow flow that increased catecholaminergic sympathetic system activities seem to be among the reasons of endothelial dysfunction.

🔖

Cite This Article

TOPAL, D., BOYRAZ, B., AKGÜMÜŞ, A., PEKER, T., YILMAZ, M., VATANSEVER, F., KANAT, S., AYDIN, Ö., ARSLAN, B. (2019). Evaluation of plasma catestatin levels in patient with coronary slow flow. The European Research Journal, Cilt: 5 - Sayı: 3, 522–528. https://ajindex.com/articles/362620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries --a new angiographic finding. Am Heart J 1972;84:66-71
  2. Lierde JV, Vrolix M, Sionis D, De Geest H, et al. Piessens J. Lack of evidence for small vessel disease in a patient with ‘slow dye progression’ in the coronary arteries. Cathet Cardiovasc Diagn 1991;23:117-20
  3. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 2010;32: 278-87
  4. Mahapatra NR. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 2008;80:330-8
  5. Brunner F, Bras-Silva C, Cerdeira AS,Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006;111:508-31
  6. Luscher TF, Tanner FC. Endothelial regulation of vascular tone and growth. Am J Hypertens 1993;6(7 Pt 2):283-93
  7. Tamirisa P, Frishman WH, Kumar A. Endothelin and endothelin antagonism: roles in cardiovascular health and disease. Am Heart J 1995;130(3 Pt 1):601-10
  8. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997;100:1623-33
  9. Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, et al. The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008;149:4780-93
  10. Liu L, Ding W, Li R, Ye X, Zhao J, Jiang J, et al. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides 2013;46:20-5
  11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am SocEchocardiogr 1989;2:358-67
  12. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88
  13. Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C, et al. Concentration of circulating plasma endothelin in patients wi